Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: HALO

Halozyme Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for HALO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$3.42

Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:51 UTC.

What Halozyme Therapeutics, Inc. does

Halozyme Therapeutics is a biopharmaceutical company that develops drug delivery technologies designed to improve how patients receive injectable medicines. The company's primary technology, ENHANZE, uses an enzyme called rHuPH20 to break down a natural barrier in the skin, allowing drugs to be injected under the skin more quickly and in larger volumes than traditional methods. Halozyme licenses ENHANZE to major pharmaceutical partners like Roche, Pfizer, and Eli Lilly, and earns revenues through upfront fees, milestone payments, and royalties from commercial products.

Summarized from Halozyme Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$3.42
Return on equity649.18%
Debt/equity13.50

Revenue, margins & earnings

FY2021 Revenue: $443M — margin split not shown (non-operating gains)$443MFY2021FY2022 Net income: $202MFY2022 Taxes & interest: $65MFY2022 Operating costs: $393M$660MFY2022FY2023 Net income: $282MFY2023 Taxes & interest: $56MFY2023 Operating costs: $492M$829MFY2023FY2024 Net income: $444MFY2024 Taxes & interest: $107MFY2024 Operating costs: $464M$1.02BFY2024FY2025 Net income: $317MFY2025 Taxes & interest: $152MFY2025 Operating costs: $928M$1.40BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-08
  • 2026-10-08PRESIDENT AND CEOSale-6,000$656.0K
  • 2026-10-08DirectorAward3,796—
  • 2026-10-08PRESIDENT AND CEOSale-900$101.5K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Halozyme Therapeutics, Inc. do?

Halozyme Therapeutics is a biopharmaceutical company that develops drug delivery technologies designed to improve how patients receive injectable medicines.

When did HALO last file with the SEC?

Halozyme Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:51 UTC. This page is also available as JSON at /api/data?ticker=HALO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for HALO and 5,000+ tickers.

Create a free account — keep HALO
For your agent
GET /api/data?ticker=HALO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt